Scholars@Duke publication: Do Medicare part D low-income subsidies narrow disparities in orally-administered antimyeloma therapy initiation?

Do Medicare part D low-income subsidies narrow disparities in orally-administered antimyeloma therapy initiation?

Publication , Conference

Jazowski, SA; Samuel-Ryals, CA; Wood, WA; Zullig, LL; Trogdon, JG; Dusetzina, SB

Published in: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

2021

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

1099-1557

1053-8569

2021

39 / 40

APA

Chicago

ICMJE

MLA

NLM

Jazowski, S. A., Samuel-Ryals, C. A., Wood, W. A., Zullig, L. L., Trogdon, J. G., & Dusetzina, S. B. (2021). Do Medicare part D low-income subsidies narrow disparities in orally-administered antimyeloma therapy initiation? In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 30, pp. 39–40).

Jazowski, Shelley A., Cleo A. Samuel-Ryals, William A. Wood, Leah L. Zullig, Justin G. Trogdon, and Stacie B. Dusetzina. “Do Medicare part D low-income subsidies narrow disparities in orally-administered antimyeloma therapy initiation?” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 30:39–40, 2021.

Jazowski SA, Samuel-Ryals CA, Wood WA, Zullig LL, Trogdon JG, Dusetzina SB. Do Medicare part D low-income subsidies narrow disparities in orally-administered antimyeloma therapy initiation? In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021. p. 39–40.

Jazowski SA, Samuel-Ryals CA, Wood WA, Zullig LL, Trogdon JG, Dusetzina SB. Do Medicare part D low-income subsidies narrow disparities in orally-administered antimyeloma therapy initiation? PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021. p. 39–40.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

1099-1557

1053-8569

2021

39 / 40